A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
© Gross et al; licensee BioMed Central Ltd. 2007
Received: 08 March 2007
Accepted: 27 July 2007
Published: 27 July 2007
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|8 Mar 2007||Submitted||Original manuscript|
|13 Apr 2007||Reviewed||Reviewer Report - Jonathan Rosenberg|
|12 Jun 2007||Reviewed||Reviewer Report - William Berry|
|15 Jun 2007||Reviewed||Reviewer Report - Damian Laber|
|28 Jun 2007||Author responded||Author comments - Mitchell Gross|
|Resubmission - Version 2|
|28 Jun 2007||Submitted||Manuscript version 2|
|12 Jul 2007||Reviewed||Reviewer Report - Jonathan Rosenberg|
|12 Jul 2007||Reviewed||Reviewer Report - Damian Laber|
|24 Jul 2007||Author responded||Author comments - Mitchell Gross|
|Resubmission - Version 3|
|24 Jul 2007||Submitted||Manuscript version 3|
|27 Jul 2007||Editorially accepted|
|27 Jul 2007||Article published||10.1186/1471-2407-7-142|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.